Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

on about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended June 30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 Sonic Innovations, Inc. (Sonic), a ... solutions, donated $10,000 to its local Feeding America ... 2009. ,, Sonic Innovations President Paul Wennerholm presented ... member, the Utah Food Bank, at the nonprofit ... participated in an office food drive and volunteered ...
(Date:12/15/2009)... -- Champions Biotechnology, Inc . (OTC Bulletin ... of advanced preclinical platforms and tumor specific data ... announced its financial results for the second fiscal ... of Company,s financial results are available in the ... Total revenues for the second quarter of 2010 ...
(Date:12/15/2009)... Dec. 15 The U.S. Food and Drug ... today voted 12 yes, 4 no, and 1 abstention ... observed risks to support the use of CRESTOR® (rosuvastatin ... Men greater than or equal to 50 years, women ... Fasting LDL < 130 mg/dL; hsCRP greater than or ...
Breaking Medicine Technology:Sonic Innovations, Inc. Donates $10,000 to Feeding America 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography 28PET 29 Myocardial Perfusion Imaging 28MPI 29 Tracer 48848 1FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography 28PET 29 Myocardial Perfusion Imaging 28MPI 29 Tracer 48848 2Nanopoint Applies CE Mark to Its cellTRAY 28R 29 Imaging and Microfluidics Systems 12612 1Nanopoint Applies CE Mark to Its cellTRAY 28R 29 Imaging and Microfluidics Systems 12612 2iCardiac Selected for Multiple Cardiac Safety Studies 12609 1iCardiac Selected for Multiple Cardiac Safety Studies 12609 2
... HIV Infection ... of Immune System Cells, ... ) today announced that it has initiated two large,Phase III ... a single 30 mg tablet in combination,with an optimized background ...
... 13 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... its clinical development and discovery,programs at four upcoming investor conferences: ... Presentation: Monday, September 17, 2007 at 10:00 a.m. ... at the St. Regis Hotel in San Francisco ...
Other Medicine Technology:Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients 2Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients 3Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients 4Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 3
(Date:12/15/2009)... Palo Alto Networks(TM), the network security ... its PA-4000 Series next-generation firewalls for accurate threat ... visibility and control over applications such as peer-to-peer ... national university with eight facilities on five campuses. ... a number of academic schools and institutions throughout ...
(Date:12/15/2009)... 15 Vitech Systems Group, a leading ... (CRM) software, announced today that it has completed ... the Screen Actors Guild-Producers Pension & Health Plans ... service capabilities to SAG-PH call center personnel in ... installed using Vitech,s V3 Benefits Administration System which ...
(Date:12/15/2009)... lower strength than needed for protection, CDC says, , , ... doses of H1N1 swine flu vaccine have been recalled ... some potency, federal health officials said Tuesday. , According ... the company,s routine testing of the vaccine for children ... four batches had lower than required potency levels. "This ...
(Date:12/15/2009)... Dec. 15 Knowledge ... the pharmaceutical and bio-tech research market with ... Over the past 11 years CMR has ... Consulting Network (PCN®), which now includes 70,000 ... both primary care and hard-to-reach specialties. ...
(Date:12/15/2009)... following are the remarks by Lanny A. ... at the Medicare Fraud Strike Force press conference: ... for the enormous effort everyone at HHS is ... our Departments have and will continue to accomplish ... progress in fighting Medicare fraud in South Florida, ...
Breaking Medicine News(10 mins):Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3
... New Poll Finds Californians Overwhelmingly Oppose Mandatory Health,Insurance, ... Calif., Jan. 15 The following,is being issued ... What:, At a press conference, a Massachusetts ... will discuss his plight and why,Californians should not ...
... Nancy Pelosi and,senior House Democrats hosted a health ... in public policy, academia, business, medicine,with key legislators ... our health care,system., "As Americans, concerns grow ... and loss of coverage, the New Direction Congress ...
... Physicians Service,Insurance Corporation (WPS) filed a lawsuit in Milwaukee ... WPS,s contractual,relationship with HealthEOS by MultiPlan, an independent primary ... terms of its contract with,WPS. This action was taken ... face with Aurora and HealthEOS to resolve these issues ...
... to data,from the 2000 US Census, Pennsylvania,s ... United States behind Florida. Widener University, in,conjunction ... "The Widener Elder Pennsylvanian Survey," aimed at ... talked to baby boomers and,centenarians about their ...
... depression, anxiety more likely to have children with airway ... born to mothers who have persistent depression or anxiety ... suggests. , Canadian researchers report a 25 percent increase ... exposed to maternal distress from birth to age 7. ...
... − Researchers at Lombardi Comprehensive Cancer Center at Georgetown ... as cyclin D1 may be the Achilles heel for ... which is the most common type of breast cancer. ... the journal Oncogene, investigators say the findings support testing ...
Other Medicine News:Health News:Massachusetts Teacher Facing Unaffordable Mandatory Health Insurance Speaks Out Against CA Mandate Proposal 2Health News:Pelosi, Democrats Host Health Care Forum This Morning 2Health News:Pelosi, Democrats Host Health Care Forum This Morning 3Health News:Pelosi, Democrats Host Health Care Forum This Morning 4Health News:Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS 2Health News:The Widener University 'Elder Pennsylvanian Survey' Finds Pennsylvania's Baby Boomers Anticipate Working Longer, Retiring Later to Help Offset Looming Health Care Costs 2Health News:The Widener University 'Elder Pennsylvanian Survey' Finds Pennsylvania's Baby Boomers Anticipate Working Longer, Retiring Later to Help Offset Looming Health Care Costs 3Health News:The Widener University 'Elder Pennsylvanian Survey' Finds Pennsylvania's Baby Boomers Anticipate Working Longer, Retiring Later to Help Offset Looming Health Care Costs 4Health News:Maternal Distress Raises Risk of Childhood Asthma 2Health News:Maternal Distress Raises Risk of Childhood Asthma 3Health News:Findings point to molecular 'Achilles heel' for half of breast cancer tumors 2Health News:Findings point to molecular 'Achilles heel' for half of breast cancer tumors 3
... of Protein C Activity by ... free of Protein C; highly ... contortrix venom for specific activation ... an activator selected specially for ...
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Medicine Products: